DOCSLIB.ORG

Emtree Terms Changed in September 2013

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Emtree Terms Changed in September 2013 Emtree Terms Added and Changed (May 2015) This is an overview of new terms added and changes made in the second Emtree release in 2015. Overall, Emtree has grown by 848 preferred terms (124 drug terms and 724 non-drug terms) compared with the previous version released in January 2015. In total Emtree now counts 71,802 preferred terms. Because the terms added include replacements for existing preferred terms (which become synonyms of the new terms) as well as completely new concepts, the number of terms added exceeds the net growth in Emtree. Other changes could include the merging of two or more existing preferred terms into a single concept. The terms added and changed are summarized below and specified in detail on the following pages. Emtree Terms Added in May 2015 1037 new terms (including 225 replacement terms and promoted synonyms) have been added to Emtree as preferred terms in version May 2015 (compared to January 2015): 172 drug terms (terms assigned to the Chemicals and Drugs facet). 901 non-drug terms (terms not assigned as Chemicals and Drugs). The new terms (including the replacement terms and the promoted synonyms) are listed as Terms Added on the following pages. Note that many of these terms will have been indexed prior to 2015 (typically as candidate terms), sometimes for several years, before they were added to Emtree. Emtree Terms Changed in May 2015 225 terms (48 drug terms and 177 non-drug terms) from Emtree January 2015 have been replaced by 220 different terms in May 2015 (48 drug terms and 172 non-drug terms). Of these, 144 terms (17 drug terms and 127 non-drug terms) are new (e.g. new generic names for drug chemical names) and have been assigned creation date 2015; the remaining 76 replacement terms (31 drug terms and 45 non-drug terms) were already present in Emtree. No drug terms were replaced by a non-drug term, no non-drug terms were replaced by a drug term. No preferred terms were deleted. Changes are presented in alphabetical order of the new terms. Emtree Terms Added in May 2015 2 Drug terms 1 (6 benzothiazolylsulfonyl) 5 chloro 1h indole 2 amlodipine plus perindopril butanoic acid antazoline plus tetryzoline 1 [2 (benzo[1,2,5]thiadiazol 5 ylamino) 6 (2,6 ascrinvacumab dichlorophenyl)pyrido[2,3 d]pyrimidin 7 yl] 3 asinercept tert butylurea Astragalus root 1 amino 4 (2 asunaprevir plus beclabuvir plus daclatasvir phenylcyclopropylamino)cyclohexane atezolizumab 1,2,3,5 tetrahydro 1 (2 isopropoxyethyl) 2 avacincaptad pegol thioxopyrrolo[3,2 d]pyrimidin 4 one avi 7537 14 o [(1 valyl 3 piperidinylthio)acetyl]mutilin avoralstat 14 o [(3 hydroxymethylphenylthio)acetyl]mutilin axalimogene filolisbac 2 (4 cyclopentylaminophenyl) 1 (2 fluoro 6 bacmid methylbenzoyl) 3 piperidinecarboxylic acid (4 balixafortide methyl 3 trifluoromethylphenyl)amide beta intermedin derivative 2 [4 [3 (4 bromophenyl)acrylamido] 3 bexaglifozin fluorophenyl] 5 benzoxazoleacetic acid bis(8 hydroxy 5 quinolinyl)[4 2 [[3 [4 [3 (diisobutylamino)propyl] 1 (trifluoromethyl)benzyl]amine piperazinyl]propyl]amino] 1h benzimidazole bismuth 207 2 hydroxy 3 (2 thienylacetamido) 1,5,2 bms 824393 dioxaborepane 7 acetic acid bovhyaluronidase azoximer 2 hydroxymethyl 2 methoxymethyl 3 Bovine viral diarrhea virus vaccine quinuclidinone brain natriuretic peptide derivative 2,2 dimethylbutyric acid brolucizumab 3 (2,3 dihydroxypropyl) 6 fluoro 5 (2 fluoro 4 calcium carbonate plus colecalciferol plus iodoanilino) 8 methylpyrido[2,3 d]pyrimidine ibandronic acid 4,7 dione calcium carbonate plus colecalciferol plus 4 [[5 [4 [4 (2 oxazolyl)phenoxy]benzyl] 2,5 zoledronic acid diazabicyclo[2.2.1]hept 2 yl]methyl]benzoic cinhyaluronic acid acid cinnarizine plus domperidone 4 amino n (3 chloro 4 fluorophenyl) n' hydroxy ciraparantag 1,2,5 oxadiazole 3 carboximidamide crisaborole 4' chloro 4 hydroxy 3 methoxychalcone dapagliflozin plus saxagliptin 5 (9 isopropyl 8 methyl 2 morpholino 9h purin 6 daprodustat yl) 2 pyrimidinamine dasabuvir plus ombitasvir plus paritaprevir plus 5 bromo n (2 propynyl) 2 (1h 1,2,4 triazol 1 yl) 4,6 ritonavir pyrimidinediamine decitabine 5,10,15,20 tetrakis(2,6 difluoro 3 n dectrekumab methylsulfamoylphenyl)bacteriochlorin derlotuximab biotin i 131 6 amino 5 [1 (2,6 dichloro 3 fluorophenyl)ethoxy] desfesoterodine n [4 (4 methyl 1 piperazinylcarbonyl)phenyl] 3 deutetrabenazine pyridazinecarboxamide dinotefuran plus pyriproxyfen 6 ethoxy 7 methoxy 2 (2 methylthiophenyl) 3,1 dusquetide benzoxazin 4 one edotreotide ga 68 [4 [(5,6 diphenyl 2 elafibranor pyrazinyl)(isopropyl)amino]butoxy]acetic acid elbasvir plus grazoprevir ach 2928 eleclazine afoxolaner plus milbemycin oxime elgemtumab aglatimagene besadenovec eltrapuldencel T akb 6548 emeramide altiratinib empagliflozin plus linagliptin amg 157 enoblituzumab amifampridine epacadostat amiselimod epetraborole amitriptyline plus chlordiazepoxide eprociclovir Emtree Terms Added in May 2015 3 erlosiban netarsudil etelcalcetide nonstructural protein 5A inhibitor fampridine olifilcon A gamma intermedin derivative olifilcon B gepotidacin olifilcon C gsk 2336805 olifilcon D guadecitabine ombitasvir plus paritaprevir plus ritonavir helper dependent adenoviral vector opicinumab hepacivirin ozanimod hepacivirin inhibitor pexidartinib heparanase inhibitor phoxilium ibiglustat pinometostat idx 320 pleuromutilin antibiotic agent immucillin A pleuromutilin derivative immucillin A triphosphate ppi 461 indimilast pterostilbene indoxacarb plus permethrin radalbuvir indusatumab ravidasvir indusatumab vedotin refanezumab infigratinib relaxin derivative irisin ridinilazole isatuximab rinucumab isunakinra rod derived cone viability factor ivacaftor plus lumacaftor roneparstat labetuzumab govitecan sacubitril plus valsartan lascufloxacin sapanisertib lavamilast seletalisib lilotomab somapacitan lilotomab satetraxetan lutetium lu 177 somavaratan lipotropin derivative spanlecortemlocel lokivetmab sparsentan lopixibat chloride stapuldencel T mereletinib streptocin merestinib tafluprost plus timolol milbemycin oxime tazemetostat motilin derivative teixobactin mycophenolate mofetil tesevatinib n (3 pyridazinyl) 4 [3 (5 trifluoromethyl 2 tesidolumab pyridinyloxy)benzylidene] 1 thymopoietin derivative piperidinecarboxamide thymosin derivative n [2 (2,3 difluorobenzylthio) 6 (2,3 dihydroxy 1 thyrotropin derivative methylpropoxy) 4 pyrimidinyl] 1 tiamulin fumarate azetidinesulfonamide tkm 100802 n [4 [2 [(4 morpholinophenyl)amino] 4 trofinetide pyrimidinyl]phenyl] 2 pyrrolidinecarboxamide vandortuzumab vedotin natriuretic peptide type C derivative vosoritide neladenoson delanate ZMapp nelonicline nemolizumab Emtree Terms Added in May 2015 4 Non-drug terms 47,XXX syndrome Antilopinae 47,XXY syndrome aorta endothelium 47,XYY syndrome Aparavirus 48,XXXX syndrome APD50 48,XXXY syndrome APD90 49,XXXXX syndrome Apophysomyces 49,XXXXY syndrome apparent dissociation constant 5-oxoprolinuria apparent permeability Abelson murine leukemia virus Apple scar skin viroid absorption rate constant Apscaviroid accumulation ratio Arabian horse Achatina architect Acinetobacter anitratus Arctocephalus Acinetobacter calcoaceticus-baumannii complex Arctocephalus gazella Actinoplanes Arctocephalus pusillus action potential amplitude area under the curve ratio activation constant area under the moment curve activation time constant Arteriviridae Acute bee paralysis virus association constant acute hepatitis A association rate constant acute hepatitis B Astragalus (plant) acute hepatitis C Astroviridae acute inflammatory demyelinating Atelinae polyneuropathy atrial fibrillation adenosine-induced hyperemia atypical teratoid rhabdoid tumor adipose fin aurochs adolescent obesity Autographivirinae adriamycin-induced nephropathy Avastrovirus Aepyceros Avian coronavirus Aeschynomene Avian erythroblastosis virus African green monkey polyomavirus Avian leukosis virus agonist potency Avian metapneumovirus AH interval Avian nephritis virus Aichi virus Avocado sunblotch viroid airway smooth muscle cell Avsunviroid AKR murine leukemia virus Avsunviroidae Alcelaphinae Bacillus globigii Alcelaphine herpesvirus 1 Bacillus thuringiensis serovar israelensis allergy patient bacterial conjunctivitis Alouattinae bacterium alpaca Banana bunchy top virus Alphacoronavirus 1 barley flour Alphanodavirus Batrachovirus Alpharetrovirus Beak and feather disease virus Alphavirus bean flour amniotic fluid stem cell Beet western yellows virus Ampelovirus Beet yellows virus anal fin Betacoronavirus 1 Andes virus Betanodavirus antagonist potency Betaretrovirus anterior byssus retractor muscle Bhanja virus anterior ethmoidal artery biceps femoris muscle anterior inferior cerebellar artery Bifidobacterium infantis Antilope biliary clearance Emtree Terms Added in May 2015 5 biochemical analysis Cebinae biochemical recurrence cecal ligation and puncture-induced sepsis biolimus eluting coronary stent central volume of distribution Black queen cell virus Cercocebus atys black-backed jackal Cercopithecinae blackbuck Cerdocyon bladder base Cerdocyon thous bladder dome cerebellum granular layer bladder sphincter prosthesis erosion cerebellum molecular layer bladder trigone cerebral artery muscle blast-induced brain injury cerebrospinal fluid-to-plasma ratio blister fluid Ceriporiopsis blood biochemistry Ceriporiopsis subvermispora blood-to-plasma ratio Chabertia body weight management chicken anemia virus bone cement leakage Chikungunya virus bovid Chlamydia muridarum bovine Chlamydiales Bovine adenovirus 3 Chloriridovirus Bovine adenovirus B cholinergic urticaria Bovine
Load more

Recommended publications
  • Minutes of the CHMP Meeting 14-17 September 2020
    13 January 2021 EMA/CHMP/625456/2020 Corr.1 Human Medicines Division Committee for medicinal products for human use (CHMP) Minutes for the meeting on 14-17 September 2020 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes Disclaimers Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 1 Addition of the list of participants Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Antibody Drug Conjugate Development in Gastrointestinal Cancers: Hopes and Hurdles from Clinical Trials
    Wu et al. Cancer Drug Resist 2018;1:204-18 Cancer DOI: 10.20517/cdr.2018.16 Drug Resistance Review Open Access Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials Xiaorong Wu, Thomas Kilpatrick, Ian Chau Department of Medical oncology, Royal Marsden Hospital NHS foundation trust, Sutton SM2 5PT, UK. Correspondence to: Dr. Ian Chau, Department of Medical Oncology, Royal Marsden Hospital NHS foundation trust, Downs Road, Sutton SM2 5PT, UK. E-mail: [email protected] How to cite this article: Wu X, Kilpatrick T, Chau I. Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials. Cancer Drug Resist 2018;1:204-18. http://dx.doi.org/10.20517/cdr.2018.16 Received: 31 Aug 2018 First Decision: 8 Oct 2018 Revised: 13 Nov 2018 Accepted: 16 Nov 2018 Published: 19 Dec 2018 Science Editors: Elisa Giovannetti, Jose A. Rodriguez Copy Editor: Cui Yu Production Editor: Huan-Liang Wu Abstract Gastrointestinal (GI) cancers represent the leading cause of cancer-related mortality worldwide. Antibody drug conjugates (ADCs) are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival. ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy. Currently, only two ADCs [brentuximab vedotin and trastuzumab emtansine (T-DM1)] have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer, respectively. Clinical research evaluating ADCs in GI cancers has shown limited success. In this review, we will retrace the relevant clinical trials investigating ADCs in GI cancers, especially ADCs targeting human epidermal growth receptor 2, mesothelin, guanylyl cyclase C, carcinogenic antigen-related cell adhesion molecule 5 (also known as CEACAM5) and other GI malignancy specific targets.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Veltuzumab, an Anti-CD20 Mab for the Treatment of Non-Hodgkin's
    Current Opinion in Molecular Therapeutics 2009 11(2):200-207 Thomson Reuters (Scientific) Ltd ISSN 2040-3445 DRUG PROFILE Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura Cannon Milani & Jorge Castillo* Address Brown University Warren Alpert Medical School, The Miriam Hospital, Division of Hematology and Oncology, 164 Summit Ave, Fain Building, Providence, RI 02906, USA Email: [email protected] *To whom correspondence should be addressed Veltuzumab is a humanized, second-generation anti-CD20 mAb currently under development by Immunomedics Inc for the potential treatment of B-cell non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Licensee Nycomed is developing veltuzumab for the potential treatment of rheumatoid arthritis and immune thrombocytopenic purpura (ITP). Veltuzumab contains 90 to 95% human antibody sequences with identical antigen framework regions to epratuzumab (a humanized anti-CD22 mAb) and similar antigen-binding determinants to rituximab (chimeric, anti-CD20 mAb and the first-line treatment of aggressive and indolent NHL). In vitro studies have demonstrated that veltuzumab has enhanced binding avidities and a stronger effect on complement-dependent cytotoxicity compared with rituximab in selected cell lines. In dose-finding phase I/II clinical trials in patients with low-grade NHL, intravenous veltuzumab demonstrated a substantial rate of complete responses in concurrence with shorter and more tolerable infusions compared with rituximab. Currently there has been no evidence of an immune response to repeated administrations, and no serious adverse events related to veltuzumab treatment in patients with NHL. Veltuzumab is undergoing clinical trials using a low-dose subcutaneous formulation in patients with NHL, CLL and ITP.
    [Show full text]
  • Malignant Pleural Mesothelioma: State- Of-The-Art on Current Therapies and Promises for the Future
    Prime Archives in Cancer Research Book Chapter Malignant Pleural Mesothelioma: State- of-the-Art on Current Therapies and Promises for the Future Fabio Nicolini1, Martine Bocchini1, Giuseppe Bronte2, Angelo Delmonte2, Massimo Guidoboni3, Lucio Crinò2 and Massimiliano Mazza1* 1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy 2Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy 3Immunotherapy and Cell Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy *Corresponding Author: Massimiliano Mazza, Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy Published January 11, 2021 This Book Chapter is a republication of an article published by Massimiliano Mazza, et al. at Frontiers in Oncology in January 2020. (Nicolini F, Bocchini M, Bronte G, Delmonte A, Guidoboni M, Crinò L and Mazza M (2020) Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. Front. Oncol. 9:1519. doi: 10.3389/fonc.2019.01519) How to cite this book chapter: Fabio Nicolini, Martine Bocchini, Giuseppe Bronte, Angelo Delmonte, Massimo Guidoboni, Lucio Crinò, Massimiliano Mazza. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. In: Heidari A, editor. Prime Archives in Cancer Research. Hyderabad, India: Vide Leaf. 2021. 1 www.videleaf.com Prime Archives in Cancer Research © The Author(s) 2021. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • ICTV Code Assigned: 2011.001Ag Officers)
    This form should be used for all taxonomic proposals. Please complete all those modules that are applicable (and then delete the unwanted sections). For guidance, see the notes written in blue and the separate document “Help with completing a taxonomic proposal” Please try to keep related proposals within a single document; you can copy the modules to create more than one genus within a new family, for example. MODULE 1: TITLE, AUTHORS, etc (to be completed by ICTV Code assigned: 2011.001aG officers) Short title: Change existing virus species names to non-Latinized binomials (e.g. 6 new species in the genus Zetavirus) Modules attached 1 2 3 4 5 (modules 1 and 9 are required) 6 7 8 9 Author(s) with e-mail address(es) of the proposer: Van Regenmortel Marc, [email protected] Burke Donald, [email protected] Calisher Charles, [email protected] Dietzgen Ralf, [email protected] Fauquet Claude, [email protected] Ghabrial Said, [email protected] Jahrling Peter, [email protected] Johnson Karl, [email protected] Holbrook Michael, [email protected] Horzinek Marian, [email protected] Keil Guenther, [email protected] Kuhn Jens, [email protected] Mahy Brian, [email protected] Martelli Giovanni, [email protected] Pringle Craig, [email protected] Rybicki Ed, [email protected] Skern Tim, [email protected] Tesh Robert, [email protected] Wahl-Jensen Victoria, [email protected] Walker Peter, [email protected] Weaver Scott, [email protected] List the ICTV study group(s) that have seen this proposal: A list of study groups and contacts is provided at http://www.ictvonline.org/subcommittees.asp .
    [Show full text]
  • Targeting EZH2 for the Treatment of Soft Tissue Sarcomas
    Karolak et al. J Cancer Metastasis Treat 2021;7:15 Journal of Cancer DOI: 10.20517/2394-4722.2021.05 Metastasis and Treatment Review Open Access Targeting EZH2 for the treatment of soft tissue sarcomas Magdalena Karolak1, Ian Tracy1, Janet Shipley2, Zoë S Walters1 1Translational Epigenomics Team, Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK. 2Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, UK. Correspondence to: Zoë S Walters, Translational Epigenomics Team, Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK. E-mail: [email protected] How to cite this article: Karolak M, Tracy I, Shipley J, Walters ZS. Targeting EZH2 for the treatment of soft tissue sarcomas. J Cancer Metastasis Treat 2021;7:15. https://dx.doi.org/10.20517/2394-4722.2021.05 Received: 7 Jan 2021 First Decision: 2 Feb 2021 Revised: 8 Feb 2021 Accepted: 25 Feb 2021 Available online: 26 Mar 2021 Academic Editor: Ian Judson Copy Editor: Yue-Yue Zhang Production Editor: Yue-Yue Zhang Abstract Soft tissue sarcomas (STS) are a heterogenous group of rare malignancies of mesenchymal origin, affecting both children and adults. The majority of STS have a poor prognosis and advanced stage at the time of diagnosis. Standard treatments for STS largely constitute tumour resection with chemotherapy and/or radiotherapy, and there has been little significant advancement in the application of novel therapies for treatment of these tumours. The current multimodal approach to therapy often leads to long-term side effects, and for some patients, resistance to cytotoxic agents is associated with local recurrence and/or metastasis.
    [Show full text]
  • 208078Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208078Orig1s000 ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 IND 106263 MEETING MINUTES Catalyst Pharmaceutical, Inc. Attention: Gary Ingenito, MD, PhD Chief Medical Officer and Head of Regulatory Affairs 355 Alhambra Circle, Suite 1250 Coral Gables, FL 33134 Dear Dr. Ingenito: Please refer to your Investigational New Drug Application (IND) submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act for amifampridine phosphate. We also refer to the meeting between representatives of your firm and the FDA on January 30, 2018. The purpose of the meeting was to review and discuss the planned contents of an NDA for amifampridine phosphate for the indication of Lambert-Eaton myasthenic syndrome and (b) (4) congenital myasthenic syndromes. A copy of the official minutes of the meeting is enclosed for your information. Please notify us of any significant differences in understanding regarding the meeting outcomes. If you have any questions, contact Laurie Kelley, Senior Regulatory Project Manager at [email protected]. Sincerely, {See appended electronic signature page} Billy Dunn, M.D. Director Division of Neurology Products Office of Drug Evaluation I Center for Drug Evaluation and Research Enclosure: Meeting Minutes Reference ID: 4216624 Reference ID: 4355913 FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH MEMORANDUM OF MEETING MINUTES Meeting Type: C Meeting Category: Guidance Meeting Date and Time: January 30, 2018 11:00am – 12:00pm EST Meeting Location: FDA White Oak, Building 22 Application Number: IND 106263 Product Name: amifampridine phosphate Indication: Lambert-Eaton myasthenic syndrome and congenital myasthenic syndromes Sponsor/Applicant Name: Catalyst Pharmaceutical, Inc.
    [Show full text]